Part 9.
TEXAS STATE BOARD OF MEDICAL EXAMINERS
Chapter 182.
USE OF EXPERTS
22 TAC §182.7
The Texas State Board of Medical Examiners proposes new §182.7,
Interim Appointment, regarding the use of Executive Committee members to make
interim appointments of expert panelists until the next board meeting.
During the two-month interval between meetings of the Medical Board, expert
panelists with specialty qualifications may be needed as part of a case investigation.
Interim appointments to the Expert Panel by a member of the Executive Committee
and follow-up ratification by the Medical Board will prevent cases from going
beyond the statutory investigatory timeline.
Michele Shackelford, General Counsel, Texas State Board of Medical Examiners,
has determined that for the first five-year period the new section is in effect
there will be no fiscal implications to state or local government as a result
of enforcing the section as proposed. There will be no effect to individuals
required to comply with the section as proposed.
Ms. Shackelford also has determined that for each year of the first five
years the new section as proposed is in effect the public benefit anticipated
as a result of enforcing the section will be to prevent cases from going beyond
the statutory investigatory timeline. There will be no effect on small or
micro businesses.
Comments on the proposal may be submitted to Colleen Klein, P.O. Box 2018,
Austin, Texas 78768-2018. A public hearing will be held at a later date.
The new rule is proposed under the authority of the Occupation
Code Annotated, §153.001 and §154.056(e), which provide that the
Texas State Board of Medical Examiners may adopt rules and bylaws as necessary
to perform its duties, regulate the practice of medicine in this state and
enforce the Medical Practice Act.
No other statutes, articles or codes are affected by this proposal.
§182.7.Interim Appointment.
A member of the Executive Committee may make an interim appointment
of an expert panelist to serve the board until the expert panelist can be
considered for appointment by the board at the next board meeting.
This agency hereby certifies that the proposal has been reviewed
by legal counsel and found to be within the agency's legal authority to adopt.
Filed with the Office of
the Secretary of State on February 18, 2005.
TRD-200500775
Donald W. Patrick, MD, JD
Executive Director
Texas State Board of Medical Examiners
Earliest possible date of adoption: April 3, 2005
For further information, please call: (512) 305-7016
Chapter 291.
PHARMACIES
Subchapter A. ALL CLASSES OF PHARMACIES
22 TAC §291.20
The Texas State Board of Pharmacy proposes amendments to §291.20,
concerning Remote Pharmacy Services. The amendments, if adopted, will implement
changes to §562.108 of the Texas Pharmacy Act made during the 78th Legislative
session which allow Class E (non-resident) pharmacies located not more than
20 miles from an institution in this state that is licensed under Chapter
242 or 252, Health and Safety Code, to maintain controlled substances and
dangerous drugs in an emergency medication kit used at an institution licensed
under those chapters; and allow a United States Department of Veterans Affairs
pharmacy or other federally operated pharmacy to maintain controlled substances
and dangerous drugs in an emergency medication kit used at an institution
that is licensed under Chapter 242, Health and Safety Code, and is a veterans
home, as defined by §164.002, Natural Resources Code. The amendments,
if adopted, also clarify inventory requirements for remote pharmacy services
using automated pharmacy systems and remote pharmacy services using emergency
medication kits; and update citations.
Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for
the first five-year period the rule is in effect, there will be no fiscal
implications for state or local government as a result of enforcing or administering
the rule.
Ms. Dodson has determined that, for each year of the first five-year period
the rule will be in effect, the public benefit anticipated as a result of
enforcing the rule will be to increase the provision of pharmacy services
within certain facilities and will clarify the inventory requirements to be
consistent in remote pharmacy services .
There is no fiscal impact for small or large businesses or to other entities
who are required to comply with this section.
Comments on the proposed amendments may be submitted to Allison Benz, R.Ph.,
M.S., Director of Professional Services, Texas State Board of Pharmacy, 333
Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments
must be received by 5 p.m., April 30, 2005.
The amendments are proposed under §§551.002, 554.051,
562.108, 562.109, and 562.110 of the Texas Pharmacy Act (Chapters 551 - 566
and 568 - 569, Texas Occupations Code). The Board interprets §551.002
as authorizing the agency to protect the public through the effective control
and regulation of the practice of pharmacy. The Board interprets §554.051(a)
as authorizing the agency to adopt rules for the proper administration and
enforcement of the Act. The Board interprets §562.108 as authorizing
the agency to adopt rules regarding emergency medication kits. The Board interprets §562.109
as authorizing the agency to adopt rules regarding automated pharmacy systems.
The Board interprets §562.110 as authorizing the agency to adopt rules
regarding telepharmacy systems.
The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 -
566 and 568 - 569, Texas Occupations Code.
§291.20.Remote Pharmacy Services.
(a)
Remote pharmacy services using automated pharmacy systems.
(1)
Purpose. The purpose of this section is to provide standards
for the provision of pharmacy services by a Class A or Class C pharmacy in
a facility that is not at the same location as the Class A or Class C pharmacy
through an automated pharmacy system as outlined in §562.109 of the Texas
Pharmacy Act (Chapters 551 - 566
and 568 - 569,
Occupations Code,
as amended).
(2) - (4)
(No change.)
(5)
Records.
(A) - (E)
(No change.)
(F)
Inventory.
(i)
A provider pharmacy shall:
(I)
(No change.)
(II)
keep a perpetual inventory of controlled substances
and other drugs required to be inventoried under §291.17 of this title,
that are
received and dispensed or distributed from each remote site.
(ii)
(No change.)
(b)
Remote pharmacy services using emergency medication kits.
(1)
Purpose. The purpose of this section is to provide standards
for the provision of pharmacy services by a Class A or Class C pharmacy in
a facility that is not at the same location as the Class A or Class C pharmacy
through an emergency medication kit as outlined in §562.108 of the Texas
Pharmacy Act (Chapters 551 - 566
and 568 - 569
, Occupations Code,
as amended).
(2)
Definitions. The following words and terms, when used in
this section, shall have the following meanings, unless the context clearly
indicates otherwise. All other words and terms shall have the meanings defined
in §291.31 of this title.
(A) - (B)
(No change.)
(C)
Emergency medication kits--controlled substances and dangerous
drugs maintained by a community pharmacy (Class A)
,
[
(D)
Remote site--a facility not located at the same location
as a Class A
,
[
(E)
(No change.)
(F)
Provider pharmacy--the community pharmacy (Class A)
,
[
(G)
(No change.)
(3)
General requirements.
(A) - (C)
(No change.)
(D)
A provider pharmacy which is licensed as an institutional
(Class C)
or a non-resident (Class E)
pharmacy is required to comply
with the provisions of §§291.31 - 291.34 of this title and this
section.
(E)
(No change.)
(4)
Operational standards.
(A)
Application for permission to provide pharmacy services
using an emergency medication kit.
(i)
A Class A
,
[
(I) - (II)
(No change.)
(III)
a statement indicating that the provider pharmacy and
the healthcare facility have entered into a written contract or agreement
which outlines the services to be provided and the responsibilities and accountabilities
of each party in fulfilling the terms of the contract or agreement in compliance
with federal and state laws and regulations; [
(IV)
documentation that the emergency medication kit is located
in a facility regulated under Chapter 242, or 252, Health and Safety Code
; and
[
(V)
documentation that the emergency kit is
located in a facility that is not more than 20 miles from the Class E pharmacy
providing the emergency kit.
(ii) - (iii)
(No change.)
(B) - (G)
(No change.)
(5)
Records.
(A) - (D)
(No change.)
(E)
Inventory.
(i)
A provider pharmacy shall:
(I)
(No change.)
(II)
keep a perpetual inventory of controlled substances
and other drugs required to be inventoried under §291.17 of this title,
that are
received and dispensed or distributed from each remote site.
(ii)
(No change.)
(c)
Remote pharmacy services using telepharmacy systems.
(1)
Purpose. The purpose of this section is to provide standards
for the provision of pharmacy services by a Class A or Class C pharmacy in
a healthcare facility that is not at the same location as a Class A or Class
C pharmacy through a telepharmacy system as outlined in §562.110 of the
Texas Pharmacy Act, Chapter 551 - 566
and 568 - 569
, Occupations
Code.
(2) - (5)
(No change.)
(d)
(No change.)
This agency hereby certifies that the proposal has been reviewed
by legal counsel and found to be within the agency's legal authority to adopt.
Filed with the Office of
the Secretary of State on February 18, 2005.
TRD-200500756
Gay Dodson, R.Ph.
Executive Director/Secretary
Texas State Board of Pharmacy
Earliest possible date of adoption: April 3, 2005
For further information, please call: (512) 305-8028
22 TAC §291.33
The Texas State Board of Pharmacy proposes amendments to §291.33,
concerning Operational Standards. The amendments, if adopted, will implement
a portion of the recommendations of the Task Force on Patient Counseling requiring
a pharmacist to ensure that the patient or patient's agent is offered information
about refill prescriptions and requiring pharmacies to post notification in
the pharmacy that a pharmacist is available to answer questions about prescription
medications. In addition, the amendments, regarding generic substitution if
adopted, will make changes to conform with proposed changes in §309.7
published elsewhere in this issue of the
Texas Register
.
Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for
the first five-year period the rule is in effect, there may be financial savings
to state and local governments. The LBB report estimates that allowing generic
substitution of products not listed in the Orange Book would reduce the state's
expenditure for prescription drugs for Medicaid by at least $9.9 million in
All Funds for the 2006-2007 biennium. According to the LBB report, approximately
$3.9 million of this amount could be saved for the General Revenue Fund.
Ms. Dodson has determined that, for each year of the first five-year period
the rule will be in effect, the public benefit anticipated as a result of
enforcing the rule will be requiring pharmacists to ensure that the patient
or patient's agent is offered information about refill prescriptions and patient's
are made aware of the availability of a pharmacist to answer questions about
prescription medications. In addition, the public benefit anticipated as a
result of enforcing the rule will be allowing the substitution of products
not listed in the Orange Book saving patients and the State of Texas money.
There is no fiscal impact for small or large businesses or to other entities
who are required to comply with this section.
Comments on the proposed amendments may be submitted to Allison Benz, R.Ph.,
M.S., Director of Professional Services, Texas State Board of Pharmacy, 333
Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments
must be received by 5 p.m., April 30, 2005.
The amendments are proposed under §551.002 and §554.051
of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations
Code). The Board interprets §551.002 as authorizing the agency to protect
the public through the effective control and regulation of the practice of
pharmacy. The Board interprets §554.051(a) as authorizing the agency
to adopt rules for the proper administration and enforcement of the Act.
The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 -
566 and 568 - 569, Texas Occupations Code.
§291.33.Operational Standards.
(a) - (b)
(No change.)
(c)
Prescription dispensing and delivery.
(1)
Patient counseling and provision of drug information.
(A)
(No change.)
(B)
Such communication:
(i)
shall be provided with each new prescription drug order[
(ii) - (iv)
(No change.)
(C) - (D)
(No change.)
(E)
In addition to the requirements of subparagraphs (A) -
(D) of this paragraph, if a prescription drug order is delivered to the patient
at the pharmacy, the following is applicable.
(i)
So that a patient will have access to information concerning
his or her prescription, a prescription may not be delivered to a patient
unless a pharmacist is in the pharmacy, except as provided in subsection (b)
(3)
[
(ii) - (iv)
(No change.)
(F)
(No change.)
(G)
Except as specified in subparagraph (B)
of this paragraph, in the best interest of the public health and to optimize
drug therapy, upon delivery of a refill prescription, a pharmacist shall ensure
that the patient or patient's agent is offered information about the refilled
prescription. Either a pharmacist or other pharmacy personnel shall inform
the patient or patient's agent that a pharmacist is available to discuss the
patient's prescription and provide information.
(H)
A pharmacy shall post a sign no smaller
than 8.5 inches by 11 inches in clear public view at all locations in the
pharmacy where a patient may pick up prescriptions. The sign shall contain
the following statement in a font that is easily readable: "Do you have questions
about your prescription? Ask the pharmacist." Such notification shall be in
both English and Spanish.
(I)
[
(2)
(No change.)
(3)
Generic Substitution.
(A) - (C)
(No change.)
(D)
Refills.
(i)
(No change.)
(ii)
Narrow therapeutic index drugs.
(I)
The board, in consultation with the Texas State Board of
Medical Examiners, has determined that no drugs shall be included on a list
of narrow therapeutic index drugs as defined in §562.013, Occupations
Code. [
(-a-)
The board has specified in §309.7 of this title
(relating to dispensing responsibilities) that for drugs listed in the publication,
pharmacists shall use as a basis for determining gerenic equivalency, Approved
Drug Products with Therapeutic Equivalence Evaluations and current supplements
published by the Federal Food and Drug Administration, within the limitations
stipulated in that publication.
Pharmacists may only substitute products
that are rated therapeutically equivalent in the Approved Drug Products with
Therapeutic Equivalence Evaluations and current supplements.
(-b-)
(No change.)
(II)
(No change.)
(4) - (7)
(No change.)
(d) - (i)
(No change.)
This agency hereby certifies that the proposal has been reviewed
by legal counsel and found to be within the agency's legal authority to adopt.
Filed with the Office of
the Secretary of State on February 18, 2005.
TRD-200500757
Gay Dodson, R.Ph.
Executive Director/Secretary
Texas State Board of Pharmacy
Earliest possible date of adoption: April 3, 2005
For further information, please call: (512) 305-8028
22 TAC §291.104
The Texas State Board of Pharmacy proposes amendments to §291.104,
concerning Generic Substitution. The amendments, if adopted, will make changes
to conform with proposed changes in §309.7 published elsewhere in this
issue of the
Texas Register
.
Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for
the first five-year period the rule is in effect, there may be financial savings
to state and local governments. The LBB report estimates that allowing generic
substitution of products not listed in the Orange Book would reduce the state's
expenditure for prescription drugs for Medicaid by at least $9.9 million in
All Funds for the 2006-2007 biennium. According to the LBB report, approximately
$3.9 million of this amount could be saved for the General Revenue Fund.
Ms. Dodson has determined that, for each year of the first five-year period
the rule will be in effect, the public benefit anticipated as a result of
enforcing the rule will be allowing the substitution of products not listed
in the Orange Book saving patients and the State of Texas money.
There is no fiscal impact for small or large businesses or to other entities
who are required to comply with this section.
Comments on the proposed amendments may be submitted to Allison Benz, R.Ph.,
M.S., Director of Professional Services, Texas State Board of Pharmacy, 333
Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments
must be received by 5 p.m., April 30, 2005.
The amendments are proposed under §551.002 and §554.051
of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations
Code). The Board interprets §551.002 as authorizing the agency to protect
the public through the effective control and regulation of the practice of
pharmacy. The Board interprets §554.051(a) as authorizing the agency
to adopt rules for the proper administration and enforcement of the Act. Section
554.051(b) which authorizes the agency to make a rule concerning the operation
of a licensed pharmacy located in this state applicable to a pharmacy licensed
by the board that is located in another state, if the board determines the
rule is necessary to protect the health and welfare of the citizens of this
state.
The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 -
566 and 568 - 569, Texas Occupations Code.
§291.104.Operational Standards.
(a) - (b)
(No change.)
(c)
Generic Substitution. Unless compliance would violate the
pharmacy or drug laws or rules in the state in which the pharmacy is located:
(1)
(No change.)
(2)
Pharmacists shall use as a basis for the determination
of generic equivalency as defined in the Subchapter A, Chapter 562 of the
Act, the following
[
(A)
For drugs listed in the publication,
pharmacists shall use Approved Drug Products with Therapeutic Equivalence
Evaluations (Orange Book) and current supplements published by the Federal
Food and Drug Administration, within the limitations stipulated in that publication,
to determine generic equivalency. Pharmacists may only substitute products
that are rated therapeutically equivalent in the Orange Book and have an "A"
rating. "A" rated drug products include but are not limited to, those designated
AA, AB, AN, AO, AP, or AT in the Orange Book.
(B)
For drugs not listed in the
Orange Book, pharmacists shall use their professional judgment to determine
generic equivalency.
(d) - (f)
(No change.)
This agency hereby certifies that the proposal has been reviewed
by legal counsel and found to be within the agency's legal authority to adopt.
Filed with the Office of
the Secretary of State on February 18, 2005.
TRD-200500759
Gay Dodson, R.Ph.
Executive Director/Secretary
Texas State Board of Pharmacy
Earliest possible date of adoption: April 3, 2005
For further information, please call: (512) 305-8028
22 TAC §295.13
The Texas State Board of Pharmacy proposes amendments to §295.13,
concerning Drug Therapy Management by a Pharmacist under Written Protocol
of a Physician. The amendments, if adopted, will delete the requirement for
pharmacists participating in drug therapy management under the written protocol
of a physician to notify the Board of participation.
Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for
the first five-year period the rule is in effect, there will be no fiscal
implications for state or local government as a result of enforcing or administering
the rule.
Ms. Dodson has determined that, for each year of the first five-year period
the rule will be in effect, the public benefit anticipated as a result of
enforcing the rule will be to clarify the notification requirements for pharmacists
participating in drug therapy management under the written protocol of a physician.
There is no fiscal impact for small or large businesses or to other entities
who are required to comply with this section.
Comments on the proposed amendments may be submitted to Allison Benz, R.Ph.,
M.S., Director of Professional Services, Texas State Board of Pharmacy, 333
Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments
must be received by 5 p.m., April 30, 2005.
The amendments are proposed under §551.002 and §554.051
of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations
Code). The Board interprets §551.002 as authorizing the agency to protect
the public through the effective control and regulation of the practice of
pharmacy. The Board interprets §554.051(a) as authorizing the agency
to adopt rules for the proper administration and enforcement of the Act. The
Board interprets §554.051(c) as authorizing the agency to adopt rules
regarding records to be maintained by a pharmacist performing a specific act
under a written protocol.
The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 -
566 and 568 - 569, Texas Occupations Code.
§295.13.Drug Therapy Management by a Pharmacist under Written Protocol of a Physician.
(a)
(No change.)
(b)
Definitions. The following words and terms, when used in
this section, shall have the following meanings, unless the context clearly
indicates otherwise.
(1)
Act--The Texas Pharmacy Act, Chapter 551 - 566
and
568 - 569
, Occupations Code, as amended.
(2) - (6)
(No change.)
(c)
Pharmacist Training Requirements
[
(1)
Initial
requirements.
[
[
[
[
(A)
[
(B)
[
(2)
Continuing requirements. A pharmacist engaged in drug therapy
management shall [
[
[
(d) - (g)
(No change.)
This agency hereby certifies that the proposal has been reviewed
by legal counsel and found to be within the agency's legal authority to adopt.
Filed with the Office of
the Secretary of State on February 18, 2005.
TRD-200500758
Gay Dodson, R.Ph.
Executive Director/Secretary
Texas State Board of Pharmacy
Earliest possible date of adoption: April 3, 2005
For further information, please call: (512) 305-8028
22 TAC §§309.2, 309.3, 309.7
The Texas State Board of Pharmacy proposes amendments to §309.2,
concerning Definitions, §309.3, concerning Generic Substitution and §309.7,
concerning Dispensing Responsibilities. The amendments, if adopted, will implement
recommendations made by the Legislative Budget Board Staff Performance Report
to the 79th Legislature to allow the substitution of products not listed in
the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic
Equivalence Evaluations (Orange Book). In addition, the amendments to §309.2,
if adopted, will correct definitions to conform with definitions in Chapter
291.
Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for
the first five-year period the rules are in effect, there may be financial
savings to state and local governments as follows:
Figure: 22 TAC Chapter 309--Preamble
The LBB report estimates that allowing generic substitution of products
not listed in the Orange Book would reduce the state's expenditure for prescription
drugs for Medicaid by at least $9.9 million in All Funds for the 2006-2007
biennium. According to the LBB report, approximately $3.9 million of this
amount could be saved for the General Revenue Fund.
Ms. Dodson has determined that, for each year of the first five-year period
the rules will be in effect, the public benefit anticipated as a result of
enforcing the rules will be allowing the substitution of products not listed
in the Orange Book saving patients and the State of Texas money.
There is no fiscal impact for small or large businesses or to other entities
who are required to comply with the sections.
Comments on the proposed amendments may be submitted to Allison Benz, R.Ph.,
M.S., Director of Professional Services, Texas State Board of Pharmacy, 333
Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments
must be received by 5 p.m., April 30, 2005.
The amendments are proposed under §551.002 and §554.051
of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations
Code). The Board interprets §551.002 as authorizing the agency to protect
the public through the effective control and regulation of the practice of
pharmacy. The Board interprets §554.051(a) as authorizing the agency
to adopt rules for the proper administration and enforcement of the Act.
The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 -
566 and 568 - 569, Texas Occupations Code.
§309.2.Definitions.
The following words and terms, when used in this chapter, shall have
the following meanings, unless the context clearly indicates otherwise. Any
term not defined in this section shall have the definition set out in the
Act, §551.003 and Chapter 562.
(1)
Act--The Texas Pharmacy Act, Occupations Code, Subtitle
J, as amended.
(2)
Data communication device--An electronic device that receives
electronic information from one source and transmits or routes it to another
(e.g., bridge, router, switch, or gateway).
(3)
Electronic prescription drug order--A prescription drug
order which is transmitted by an electronic device to the receiver (pharmacy).
[
[
(4)
[
(5)
[
(6)
[
(7)
[
(A)
original written prescription drug orders; or
(B)
original verbal or electronic prescription drug orders
reduced to writing either manually or electronically by the pharmacist.
(8)
[
(A)
A person licensed or registered to prescribe, distribute,
administer, or dispense a prescription drug or device in the course of professional
practice in this state, including a physician, dentist, podiatrist, therapeutic
optometrist, or veterinarian but excluding a person licensed under this subtitle;
(B)
A person licensed by another state, Canada, or the United
Mexican States in a health field in which, under the law of this state, a
license holder in this state may legally prescribe a dangerous drug;
(C)
A person practicing in another state and licensed by another
state as a physician, dentist, veterinarian, or podiatrist, who has a current
federal Drug Enforcement Administration registration number and who may legally
prescribe a Schedule II, III, IV, or V controlled substance, as specified
under Chapter 481, Health and Safety Code, in that other state; or
(D)
An advanced practice nurse or physician assistant to whom
a physician has delegated the authority to carry out or sign prescription
drug orders under §§157.052, 157.053, 157.054, 157.0541, or 157.0542,
Occupations Code.
§309.3.Generic Substitution.
(a) - (d)
(No change.)
(e)
Refills.
(1)
(No change.)
(2)
Narrow therapeutic index drugs.
(A)
The board, in consultation with the Texas State Board of
Medical Examiners, has determined that no drugs shall be included on a list
of narrow therapeutic index drugs as defined in §562.013, Occupations
Code. [
(i)
The board has specified in §309.7 of this title
(relating to dispensing responsibilities) that for drugs listed in the publication,
pharmacist shall use as a basis for determining generic equivalency, Approved
Drug Products with Therapeutic Equivalence Evaluations and current supplements
published by the Federal Food and Drug Administration, within the limitations
stipulated in that publication. For drugs listed in the publications, pharmacists
[
(ii)
(No change.)
(B)
(No change.)
§309.7.Dispensing Responsibilities.
(a)
The determination of the drug product to be substituted
as authorized by the Subchapter A, Chapter 562 of the Act, is the professional
responsibility of the pharmacist, and the pharmacist may not dispense any
product that does not meet the requirements of the Subchapter A, Chapter 562
of the Act.
As specified in Chapter 562 of the Act and §309.2 of
this title (relating to definitions), a generically equivalent product is
one that is pharmaceutically equivalent and therapeutically equivalent to
the drug prescribed.
(b)
Pharmacists shall
use
[
(1)
For drugs listed in the publication,
pharmacists shall use Approved Drug Products With Therapeutic Equivalence
Evaluations (Orange Book) and current supplements published by the Federal
Food and Drug Administration, within the limitations stipulated in that publication,
to determine generic equivalency. Pharmacists may only substitute products
that are rated therapeutically equivalent in the Orange Book and have an "A"
rating. "A" rated drug products include but are not limited to, those designated
AA, AB, AN, AO, AP, or AT in the Orange Book.
(2)
For drugs not listed in the
Orange Book, pharmacists shall use their professional judgment to determine
generic equivalency.
[
This agency hereby certifies that the proposal has been reviewed
by legal counsel and found to be within the agency's legal authority to adopt.
Filed with the Office of
the Secretary of State on February 18, 2005.
TRD-200500760
Gay Dodson, R.Ph.
Executive Director/Secretary
Texas State Board of Pharmacy
Earliest possible date of adoption: April 3, 2005
For further information, please call: (512) 305-8028
Chapter 851.
TEXAS BOARD OF PROFESSIONAL GEOSCIENTISTS LICENSING RULES
Subchapter A. LICENSING
22 TAC §851.32
The Texas Board of Professional Geoscientists (TBPG) proposes
22, Texas Administrative Code Chapter 851, §851.32, concerning continuing
education. This newly proposed rule establishes both requirements and procedures
related to the continuing education of licensed geoscientists in the State
of Texas. Legislation enactment in 2001 of Senate Bill 405 required the Texas
Board of Professional Geoscientists to adopt and implement a recommended timeline
and criteria by which continuing education rules would be established that
would enable licensed geoscientists to renew their licenses. The proposed
rule provides language clarifying the agency's requirement of number of educational
hours as well as acceptable courses applicable to continuing education. The
need for this clarification is based on feedback from the geological community
in the agency's initial year of operation.
Michael D. Hess, Executive Director of the Texas Board of Professional
Geoscientists, has determined that for the first five years that this rule
is in effect there will be no fiscal implication for state and local government
as a result of enforcement and administration of this section.
Mr. Hess has also determined that for each year of the first five years
that this section is in effect, the State of Texas can anticipate public benefit
as a result of enforcement and enhancement of the professional practice of
geology through the requirement of an increased level of education for the
geoscience licensed population. There will not be an effect on small or micro
businesses, however it is anticipated that there will be an economic cost
to licensees in order to take the required educational courses.
Comments on the proposal may be submitted in writing to Michael D. Hess,
Executive Director, P.O. Box 13225, Austin, Texas 78701, (512) 936-4401. Comments
may also be submitted electronically to
geoscience@tbpg.state.tx.us
or faxed to (512) 936-4409. All comments must be received 30 days
after publication of this rule in the
Texas Register
. All requests for a public hearing on the proposed section submitted
under the Administrative Procedure Act must be received by the Executive Director
not more than 15 calendar days after notice of a proposed new section has
been published in the
Texas Register
.
The new section is proposed under the Texas Occupations Code,
Chapter 1002, which authorizes the Board to adopt a mandated continuing education
process and criteria by which all licensees will participate prior to their
annual license renewal.
The proposed section implements the Texas Occupations Code, §1002.302.
§851.32.Continuing Education Program.
(a)
Each license holder shall meet the Continuing Education
Program (CEP) requirements for professional development as a condition for
license renewal.
(b)
Terms used in this section are defined as follows:
(1)
Professional Development Hour (PDH)--A contact hour (clock
hour) of CEP activity. PDH is the basic unit for CEP reporting.
(2)
Continuing Education Unit (CEU)--Unit of credit customarily
used for continuing education courses. One continuing education unit equals
10 hours of class in an approved continuing education course.
(3)
College/Unit Semester/Quarter Hour--Credit for course in
a discipline of geoscience or other related technical elective of the discipline.
(4)
Course/Activity--Any qualifying course or activity with
a clear purpose and objective which will maintain, improve, or expand the
skills and knowledge relevant to the license holder's field of practice.
(c)
Every license holder is required to obtain 15 PDH units
during the renewal period year.
(d)
A minimum of 1 PDH per renewal period must be in the area
of professional ethics, roles and responsibilities of professional geoscientists,
or review on-line of the Texas Geoscientist Practice Act and Board Rules.
(e)
If a license holder exceeds the annual requirement in any
renewal period, a maximum of 30 PDH units may be carried forward into the
subsequent renewal periods.
(f)
PDH units may be earned as follows:
(1)
Successful completion or auditing of college credit courses.
(2)
Successful completion of continuing education courses,
either offered by a professional or trade organization, university or college,
or offered in-house by a corporation, other business entity, professional
or technical societies, associations, agencies, or organizations, or other
group.
(3)
Successful completion of correspondence, on-line, televised,
videotaped, and other short courses/tutorials.
(4)
Presenting or attending qualifying seminars, in-house courses,
workshops, or professional or technical presentations made at meetings, conventions,
or conferences sponsored by a corporation, other business entity, professional
or technical societies, associations, agencies, or organizations, or other
group.
(5)
Teaching or instructing as listed in paragraphs (1) - (4)
of this section.
(6)
Authoring published papers, articles, books, or accepted
licensing examination items.
(7)
Active participation in professional or technical societies,
associations, agencies, or organizations, including:
(A)
Serving as an elected or appointed official;
(B)
Serving on a committee of the organization;
(C)
Serving in other official positions.
(8)
Patents Issued.
(9)
Engaging in self-directed course work.
(10)
Software Programs Published.
(g)
All activities described in subsection (f) of this section
shall be relevant to the practice of a discipline of geoscience and may include
technical, ethical, or managerial content.
(h)
The conversion of other units of credit to PDH units is
as follows and subject to subsection (g) of this section
(1)
1 College or unit semester hour--15 PDH
(2)
1 College or unit quarter hour--10 PDH
(3)
1 Continuing Education Unit--10 PDH
(4)
1 Hour of professional development in course work, seminars,
or professional or technical presentations made at meetings, conventions,
or conferences--1 PDH
(5)
1 Hour of professional development through self-directed
course study (Not to exceed 5 PDH)--1 PDH
(6)
Each published paper or article--10 PDH and book--45 PDH
(7)
Active participation, as defined in subsection (f)(7) of
this section, in professional or technical society, association, agency, or
organization (Not to exceed 5 PDH per year)--1 PDH
(8)
Each patent issued--15 PDH
(9)
Each software program published--15 PDH
(10)
Teaching or instructing as described in subsection (f)(5)
of this section--3 times the PDH credit earned.
(i)
Determination of Credit
(1)
The Board shall be the final authority with respect to
whether a course or activity meets the requirements of these rules.
(2)
The Board shall not pre-approve or endorse any CEP activities
during the first two years after the effective date of this rule. It is the
responsibility of each license holder to assure that all PDH credits claimed
meet CEP requirements. However, a course provider may contact the Board for
an opinion for whether or not a course or technical presentation would meet
the CEP requirements. Two years after the effective date of this rule, pre-approval
will be required.
(3)
Credit for college or community college approved courses
will be based upon course credit established by the college.
(4)
Credit for qualifying seminars and workshops will be based
on one PDH unit for each hour of attendance. Attendance at qualifying programs
presented at professional and/or technical society meetings will earn PDH
units for the actual time of each program.
(5)
Credit for self-directed course work will be based on one
PDH unit for each hour of study and is not to exceed 5 PDH per renewal period.
Credit determination for self-directed course work is the responsibility of
the license holder and subject to review as required by the board.
(6)
Credit determination for activities described in subsection
(h)(6) of this section is the responsibility of the license holder and subject
to review as required by the board.
(7)
Credit for activity described in subsection (h)(7) of this
section requires that a license holder serve as an officer of the organization,
actively participate in a committee of the organization, or perform other
activities such as making or attending a presentation at a meeting or writing
a paper presented at a meeting. PDH credits are not earned until the end of
each year of service is completed.
(8)
Teaching credit, as defined in subsection (f)(5) of this
section, is valid for teaching a course or seminar for the first time only.
(j)
The license holder is responsible for maintaining records
to be used to support credits claimed. Records required include, but are not
limited to:
(1)
A log, on a form provided by TBPG, showing the type of
activity claimed, sponsoring organization, location, duration, instructor's
or speaker's name, and PDH credits earned; and
(2)
Attendance verification records in the form of completion
certificates, receipts, attendance roster, or other documents supporting evidence
of attendance.
(k)
The license holder must submit CEP certification on the
log form provided by TBPG and a list of each activity, date, and hours claimed
that satisfy the CEP requirement for that renewal year when audited. A percentage
of the licenses will be randomly audited each year.
Figure: 22 TAC §851.32(k) (.pdf)
(l)
CEP records for each license holder must be maintained
for a period of three years by the license holder.
(m)
CEP records for each license holder are subject to audit
by the board or its authorized representative.
(1)
Copies must be furnished, if requested, to the Board or
its authorized representative for audit verification purposes.
(2)
If upon auditing a license holder, the Board finds that
the activities cited do not fall within the bounds of educational, technical,
ethical, or professional management activities related to the practice of
geoscience; the board may require the license holder to acquire additional
PDH as needed to fulfill the minimum CEP requirements.
(n)
A license holder may be exempt from the professional development
educational requirements for one of the following reasons listed in paragraphs
(1) - (5) of this subsection:
(1)
New license holders by way of examination shall be exempt
for their first renewal period.
(2)
A license holder serving on active duty and deployed outside
the United States, its possessions and territories, in or for the military
service of the United States for a period of time exceeding one hundred twenty
(120) consecutive days in a year shall be exempt from obtaining the professional
development hours required during that year.
(3)
A license holder employed outside the United States, its
possessions and territories, actively engaged in the practice of geoscience
for a period of time exceeding three hundred (300) consecutive days in a year
shall be exempt from obtaining the professional development hours required
during that year except for five (5) hours of self-directed course work.
(4)
License holders who list their status as "Inactive" and
who further certify that they are no longer receiving any remuneration from
providing professional geoscience services in Texas shall be exempt from the
professional development hours required.
(5)
License holders experiencing long term physical disability
or illness. may be exempt by applying for "inactive" status. Supporting documentation
must be furnished to the board.
(o)
A license holder may bring an inactive license to active
status by obtaining all delinquent PDH units. However, if the total number
required to become current exceeds 30 units, then 30 units shall be the maximum
number required.
(p)
Noncompliance:
(1)
If a license holder does not certify that CEP requirements
have been met for a renewal period, the license shall be considered expired
and subject to late fees and penalties.
(2)
A determination by audit that CEP requirements have been
falsely reported shall be considered to be misconduct and will subject the
license holder to disciplinary action.
This agency hereby certifies that the proposal has been
reviewed by legal counsel and found to be within the agency's legal authority
to adopt.
Filed with the Office of
the Secretary of State on February 16, 2005.
TRD-200500738
Michael D. Hess
Executive Director
Texas Board of Professional Geoscientists
Earliest possible date of adoption: April 3, 2005
For further information, please call: (512) 936-4400
Part 15.
TEXAS STATE BOARD OF PHARMACY
or
]
an institutional pharmacy (Class C) at an institution licensed under Chapter
242 or 252, Health and Safety Code,
a non-resident (Class E) pharmacy
located not more than 20 miles from an institution licensed under Chapter
242 or 252, Health and Safety Code, or a United States Department of Veterans
Affairs pharmacy or another federally operated pharmacy at an institution
that is licensed under Chapter 242, Health and Safety Code, and is a veterans
home, as defined by §164.002, Natural Resources Code,
to meet the
emergency medication needs of a resident at that institution.
or
] Class C
, Class E pharmacy or
a United States Department of Affairs pharmacy or another federally operated
pharmacy, at which remote pharmacy services are provided using an emergency
medication kit.
or
] the institutional pharmacy (Class C)
, the non-resident
(Class E) pharmacy located not more than 20 miles from an institution licensed
under Chapter 242 or 252, Health and Safety Code, or the United States Department
of Veterans Affairs pharmacy or another federally operated pharmacy
providing
remote pharmacy services.
or
] Class C
, or
Class E
Pharmacy shall make application to the board to provide remote
pharmacy services using an emergency medication kit. The application shall
contain an affidavit with the notarized signatures of the pharmacist-in-charge,
and the medical director or the person responsible for the on-site operation
of the facility (e.g., administrator, owner, chief executive officer, chief
operating officer), and include the following:
and
]
.
]
Subchapter B. COMMUNITY PHARMACY (CLASS A)
, once yearly on maintenance medications, and if the pharmacist deems appropriate,
with prescription drug order refills. (For the purposes of this clause, maintenance
medications are defined as any medication the patient has taken for one year
or longer)
];
(4)
] of this section or clause (ii) of this subparagraph.
(G)
] The provisions of this paragraph
do not apply to patients in facilities where drugs are administered to patients
by a person required to do so by the laws of the state (i.e., nursing homes).
The board has specified in §309.7 of this title (relating
to dispensing responsibilities) that pharmacist shall use as a basis for determining
generic equivalency, Approved Drug Products with Therapeutic Equivalence Evaluations
and current supplements published by the Federal Food and Drug Administration,
within the limitations stipulated in that publication.
]
Subchapter F. NON-RESIDENT PHARMACY (CLASS E)
provided the pharmacist uses as a basis for
the determination of generic equivalency, the publication, Approved Drug Products
With Therapeutic Equivalence Evaluations and current supplements published
by the Federal Food and Drug Administration within the limitations stipulated
in that publication
].
Chapter 295.
PHARMACISTS
Notification
].
notification. Prior
to initially engaging in drug therapy management, a
]
A
pharmacist
shall
maintain and provide to the Board within 24 hours of request
[
provide the board with:
]
(A)
the name, license number,
and address of the supervising physician; ]
(B)
the address where the records
of such drug therapy management are maintained; and ]
(C)
]
a statement attesting to the fact that the
pharmacist has within the last year:
(i)
] completed at least six hours
of continuing education related to drug therapy offered by a provider approved
by the
Accreditation Council for Pharmacy Education
[
American
Council on Pharmaceutical Education
] (ACPE); or
(ii)
] engaged in drug therapy management
as allowed under previous laws or rules. A statement from the physician supervising
the acts shall be sufficient documentation.
:
]
(A)
]
annually complete six hours of continuing
education related to drug therapy offered by a provider approved by the
Accreditation Council for Pharmacy Education
[
American Council
on Pharmaceutical Education
] (ACPE). (These hours may be applied towards
the hours required for renewal of a license to practice pharmacy.)
(B)
notify the board of any change
in supervising physician or change in the address where the records of drug
therapy management are maintained. ]
Chapter 309.
GENERIC SUBSTITUTION
Electronic prescription drug order includes computer to computer transmission,
but does not include facsimile prescription drug orders.
]
(4)
Facsimile prescription drug
order--A prescription drug order which is transmitted by an electronic device
which sends an exact image to the receiver (pharmacy).]
(5)
] Generically equivalent--A
drug that is pharmaceutically equivalent and therapeutically equivalent to
the drug prescribed.
(6)
] Pharmaceutically equivalent--Drug
products that have identical amounts of the same active chemical ingredients
in the same dosage form and that meet the identical compendial or other applicable
standards of strength, quality, and purity according to the United States
Pharmacopoeia or another nationally recognized compendium.
(7)
] Therapeutically equivalent--Pharmaceutically
equivalent drug products that, if administered in the same amounts, will provide
the same therapeutic effect, identical in duration and intensity.
(8)
] Original prescription--The:
(9)
] Practitioner--
The board has specified in §309.7 of this title (relating
to dispensing responsibilities) that pharmacist shall use as a basis for determining
generic equivalency, Approved Drug Products with Therapeutic Equivalence Evaluations
and current supplements published by the Federal Food and Drug Administration,
within the limitations stipulated in that publication.
]
Pharmacists
] may only substitute products that are rated
therapeutically equivalent in the Approved Drug Products with Therapeutic
Equivalence Evaluations and current supplements.
utilize
] as
a basis for the determination of generic equivalency as defined in the Subchapter
A, Chapter 562 of the Act,
the following:
[
Approved Drug Products
With Therapeutic Equivalence Evaluations (Orange Book) and current supplements
published by the Federal Food and Drug Administration, within the limitations
stipulated in that publication.
]
(c)
Pharmacists may only substitute
products that are rated therapeutically equivalent in the Orange Book and
have an "A" rating. "A" rated drug products include but are not limited to,
those designated AA, AB, AN, AO, AP, or AT in the Orange Book.]
Part 39.
TEXAS BOARD OF PROFESSIONAL GEOSCIENTISTS